Send us Feedback

Advanced Medical Optics (EYE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
OPERATING METRICS
REVENUE SOURCES
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

EYE » Topics » Fourth-Quarter and Full-Year 2007 Sales Performance by Business

This excerpt taken from the EYE 8-K filed Feb 14, 2008.

Fourth-Quarter and Full-Year 2007 Sales Performance by Business

Below are highlights of fourth-quarter and full-year 2007 results by business. Growth rates reflect comparisons to the same period in 2006 and include foreign currency impacts. Pro forma growth rates reflect comparisons that include IntraLase and WaveFront Sciences performance as if these acquisitions had occurred in all periods presented. For more information, see the “Global Sales” table accompanying this release.

Cataract/Implant sales rose 9.6% to $152.3 million in the quarter and 6.4% to $552.0 million for 2007.

 

 

•

  

Intraocular lens (IOL) sales rose 7.6% to $85.7 million in the quarter and 8.8% to $317.2 million for 2007, reflecting continuing demand for the company’s Tecnis® monofocal IOLs and its portfolio of refractive IOLs.

 

 

•

  

Viscoelastics sales rose 9.7% to $33.6 million in the quarter and 0.3% to $123.4 million for 2007. Growth was driven primarily by increased sales of the Healon® family of viscoleastics.

 

 

•

  

Phacoemulsification sales rose 10.7% to $26.4 million in the quarter and 3.6% to $90.7 million for 2007. The rise reflected the mid-year launch of the WhiteStar SignatureTM system and increased surgeon usage of the company’s existing phacoemulsification installed base. Surgical pack sales rose 12.9% in the quarter and 9.5% for 2007.

Laser Vision Correction (LVC) sales rose 96.8% to $101.7 million in the quarter and 69.6% to $367.8 million for 2007. Pro forma LVC sales rose 10.6% and 13.8% for the quarter and year, respectively.

 

  •  

Fourth-quarter procedures and related sales of $56.9 million represented a 65.8% increase, or 11.5% on a pro forma basis. For 2007, procedures and related sales of $229.1 million represented a 58.7% increase, or 24.0% on a pro forma basis. Growth reflects primarily market share gains, favorable custom mix shift and continued international expansion.

 

 

•

  

For 2007, AMO’s U.S. excimer procedure volumes grew 6.2% and its U.S. CustomVue® procedure mix was 64.4%. For 2007, AMO’s U.S. femtosecond procedure volumes grew 41.5% on a pro forma basis.

 

  •  

For 2007, international procedure sales rose 75.1% to $67.6 million, reflecting excimer procedure sales growth of 58.8% and pro forma femtosecond procedure sales growth of 84.2%.

 

  •  

Fourth-quarter system sales increased 280.9% to $36.2 million, or an increase of 21.7% on a pro forma basis. For 2007, system sales rose 154.2%, or 3.4% on a pro forma basis. The rise reflects the continued penetration of the company’s systems worldwide.

 

 

•

  

Fourth-quarter unit placements of the VISX® Star S4 IR® excimer laser declined 17%, reflecting a difficult comparison in the year-ago quarter when a significant U.S. corporate provider adopted the company’s excimer technology. For 2007, excimer laser placements rose 13.5%. IntraLase® FS laser placements rose 58.9% for the quarter and 31.4% for 2007, on a pro forma basis. The rise reflects the continued penetration of the company’s systems worldwide.

Eye Care sales declined 4.6% to $50.5 million in the quarter and 34.6% to $171.0 million for 2007. On a sequential basis, fourth-quarter eye care sales rose 19.9%.

 

 

•

  

Fourth-quarter multipurpose sales declined 16.0% to $20.1 million, which included approximately $3.8 million in returns and an estimated $29.2 million in lost sales related to the recall. For 2007, multipurpose sales declined 59.8% to $59.2 million, which included approximately $41.5 million in returns and an estimated $84.0 million in lost sales related to the recall. Sales declines in both periods were partially offset by the re-launch of Complete® Easy RubTM Multipurpose Solution.

AMO Announces Fourth-Quarter and Full Year 2007 Results – 4

 

 

•

  

For the four weeks ended January 15, 2008, Complete® Easy RubTM Multipurpose Solution held 6.7% of the U.S. branded multipurpose solution market, according to IRI.

 

  •  

Hydrogen peroxide sales rose 22.4% in the quarter to $17.0 million and declined 2.4% to $60.8 million for 2007.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki